1
|
Sforzi J, Lanfranco A, Stefania R, Alberti D, Bitonto V, Parisotto S, Renzi P, Protti N, Altieri S, Deagostino A, Geninatti Crich S. A novel pH sensitive theranostic PLGA nanoparticle for boron neutron capture therapy in mesothelioma treatment. Sci Rep 2023; 13:620. [PMID: 36635364 PMCID: PMC9837127 DOI: 10.1038/s41598-023-27625-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2022] [Accepted: 01/04/2023] [Indexed: 01/13/2023] Open
Abstract
This study aims to develop poly lactic-co-glycolic acid (PLGA) nanoparticles with an innovative imaging-guided approach based on Boron Neutron Capture Therapy for the treatment of mesothelioma. The herein-reported results demonstrate that PLGA nanoparticles incorporating oligo-histidine chains and the dual Gd/B theranostic agent AT101 can successfully be exploited to deliver a therapeutic dose of boron to mesothelioma cells, significantly higher than in healthy mesothelial cells as assessed by ICP-MS and MRI. The selective release is pH responsive taking advantage of the slightly acidic pH of the tumour extracellular environment and triggered by the protonation of imidazole groups of histidine. After irradiation with thermal neutrons, tumoral and healthy cells survival and clonogenic ability were evaluated. Obtained results appear very promising, providing patients affected by this rare disease with an improved therapeutic option, exploiting PLGA nanoparticles.
Collapse
Affiliation(s)
- Jacopo Sforzi
- grid.7605.40000 0001 2336 6580Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126 Turin, Italy
| | - Alberto Lanfranco
- grid.7605.40000 0001 2336 6580Department of Chemistry, University of Torino, Via P. Giuria 7, 10125 Turin, Italy
| | - Rachele Stefania
- grid.16563.370000000121663741Department of Science and Technological Innovation, Università del Piemonte Orientale, 15121 Alessandria, Italy
| | - Diego Alberti
- grid.7605.40000 0001 2336 6580Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126 Turin, Italy
| | - Valeria Bitonto
- grid.7605.40000 0001 2336 6580Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126 Turin, Italy
| | - Stefano Parisotto
- grid.7605.40000 0001 2336 6580Department of Chemistry, University of Torino, Via P. Giuria 7, 10125 Turin, Italy
| | - Polyssena Renzi
- grid.7605.40000 0001 2336 6580Department of Chemistry, University of Torino, Via P. Giuria 7, 10125 Turin, Italy
| | - Nicoletta Protti
- grid.8982.b0000 0004 1762 5736Department of Physics, University of Pavia, Via Agostino Bassi 6, 27100 Pavia, Italy ,Nuclear Physics National Institute (INFN), Unit of Pavia, Via Agostino Bassi 6, 27100 Pavia, Italy
| | - Saverio Altieri
- grid.8982.b0000 0004 1762 5736Department of Physics, University of Pavia, Via Agostino Bassi 6, 27100 Pavia, Italy ,Nuclear Physics National Institute (INFN), Unit of Pavia, Via Agostino Bassi 6, 27100 Pavia, Italy
| | - Annamaria Deagostino
- Department of Chemistry, University of Torino, Via P. Giuria 7, 10125, Turin, Italy.
| | - Simonetta Geninatti Crich
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Turin, Italy.
| |
Collapse
|
2
|
Interactions of Analgesics with Cisplatin: Modulation of Anticancer Efficacy and Potential Organ Toxicity. MEDICINA (KAUNAS, LITHUANIA) 2021; 58:medicina58010046. [PMID: 35056355 PMCID: PMC8781901 DOI: 10.3390/medicina58010046] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Revised: 12/19/2021] [Accepted: 12/20/2021] [Indexed: 12/17/2022]
Abstract
Cisplatin (CDDP), one of the most eminent cancer chemotherapeutic agents, has been successfully used to treat more than half of all known cancers worldwide. Despite its effectiveness, CDDP might cause severe toxic adverse effects on multiple body organs during cancer chemotherapy, including the kidneys, heart, liver, gastrointestinal tract, and auditory system, as well as peripheral nerves causing severely painful neuropathy. The latter, among other pains patients feel during chemotherapy, is an indication for the use of analgesics during treatment with CDDP. Different types of analgesics, such as acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDS), and narcotic analgesics, could be used according to the severity of pain. Administered analgesics might modulate CDDP’s efficacy as an anticancer drug. NSAIDS, on one hand, might have cytotoxic effects on their own and few of them can potentiate CDDP’s anticancer effects via inhibiting the CDDP-induced cyclooxygenase (COX) enzyme, or through COX-independent mechanisms. On the other hand, some narcotic analgesics might ameliorate CDDP’s anti-neoplastic effects, causing chemotherapy to fail. Concerning safety, some analgesics share the same adverse effects on normal tissues as CDDP, augmenting its potentially hazardous effects on organ impairment. This article offers an overview of the reported literature on the interactions between analgesics and CDDP, paying special attention to possible mechanisms that modulate CDDP’s cytotoxic efficacy and potential adverse reactions.
Collapse
|
3
|
Saadipour M, Karkhaneh A, Haghbin Nazarpak M. An investigation into curcumin release from PLA particles loaded in PCL-GELATIN fibers for skin application. INT J POLYM MATER PO 2020. [DOI: 10.1080/00914037.2020.1838520] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- Misagh Saadipour
- Biomedical Engineering Department, Amirkabir University of Technology (Tehran Polytechnic), Tehran, Iran
| | - Akbar Karkhaneh
- Biomedical Engineering Department, Amirkabir University of Technology (Tehran Polytechnic), Tehran, Iran
| | | |
Collapse
|
4
|
Pourtalebi Jahromi L, Ghazali M, Ashrafi H, Azadi A. A comparison of models for the analysis of the kinetics of drug release from PLGA-based nanoparticles. Heliyon 2020; 6:e03451. [PMID: 32140583 PMCID: PMC7049635 DOI: 10.1016/j.heliyon.2020.e03451] [Citation(s) in RCA: 101] [Impact Index Per Article: 25.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2019] [Revised: 07/07/2019] [Accepted: 02/17/2020] [Indexed: 12/22/2022] Open
Abstract
Purpose Poly (lactic-co-glycolic acid) has received much academic attention for developing nanotherapeutics and FDA has approved it for several applications. An important parameter that dictates the bioavailability and hence the biological effect of the drug is drug release from its delivering system. This study offers a comparative mathematical analysis of drug release from Poly (lactic-co-glycolic acid)–based nanoparticles to suggest a general model explaining multi-mechanistic release they provide. Methods Eight release models, zero order, first order, Higuchi, Hixson-Crowell, the square root of mass, the three-second root of mass, Weibull and Korsmeyer-Peppas, as well as the second degree polynomial equation were applied to 60 data sets. The models analysed regarding several types of errors, regression parameters and average Akaike information criterion. Results and discussion Most of the data sets present the highest R2, the lowest overall error and AIC for the Weibull model. Weibull model with the mean AIC = -36.37 and mean OE = 7.24 and the highest NE less than 5, 10, 15 and 20 % in most of the cases best fits the release data from various PLGA-based drug delivery systems that are studied. Weibull model seems to show enough flexibility to describe various release patterns PLGA provides.
Collapse
Affiliation(s)
| | - Mohammad Ghazali
- Department of Pharmaceutics, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Hajar Ashrafi
- Department of Pharmaceutics, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Amir Azadi
- Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.,Department of Pharmaceutics, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
| |
Collapse
|
5
|
Formulation of functionalized PLGA nanoparticles with folic acid-conjugated chitosan for carboplatin encapsulation. Eur Polym J 2018. [DOI: 10.1016/j.eurpolymj.2018.09.011] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
6
|
Vandghanooni S, Eskandani M, Barar J, Omidi Y. AS1411 aptamer-decorated cisplatin-loaded poly(lactic-co-glycolic acid) nanoparticles for targeted therapy of miR-21-inhibited ovarian cancer cells. Nanomedicine (Lond) 2018; 13:2729-2758. [PMID: 30394201 DOI: 10.2217/nnm-2018-0205] [Citation(s) in RCA: 74] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
AIM The overexpression of miRNA-21 correlates with the cisplatin (CIS) resistance in the ovarian cancers. METHODS AS1411 antinucleolin aptamer-decorated PEGylated poly(lactic-co-glycolic acid) nanoparticles containing CIS (Ap-CIS-NPs) and anti-miR-21 (Ap-anti-miR-21-NPs) were prepared, physicochemically investigated and their cancer-targeting ability was confirmed. CIS-resistant A2780 cells (A2780 R) were infected with anti-miR-21 using Ap-anti-miR-21-NPs to decrease the drug resistance and sensitize the cells to CIS. Afterward, miR-21-inhibited cells were exposed to the Ap-CIS-NPs. RESULTS Ap-anti-miR-21-NPs could infect the A2780 R cells mainly through nucleolin-mediated endocytosis and inhibit the endogenous miR-21. Targeted delivery of CIS using Ap-CIS-NPs into the miR-21-inhibited cells caused an enhanced mortality. CONCLUSION The targeted delivery of chemotherapeutics to the oncomiR-inhibited cells may find a robust application in cancer chemo/gene therapy.
Collapse
Affiliation(s)
- Somayeh Vandghanooni
- Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Morteza Eskandani
- Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Jaleh Barar
- Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran
- Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Yadollah Omidi
- Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran
- Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
7
|
Booysen E, Bezuidenhout M, van Staden ADP, Dimitrov D, Deane SM, Dicks LMT. Antibacterial Activity of Vancomycin Encapsulated in Poly(DL-lactide-co-glycolide) Nanoparticles Using Electrospraying. Probiotics Antimicrob Proteins 2018; 11:310-316. [PMID: 29961212 DOI: 10.1007/s12602-018-9437-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Vancomycin is often used to treat infections caused by β-lactam-resistant bacteria. However, methicillin-resistant strains of Staphylococcus aureus (MRSA) acquired resistance to vancomycin, rendering it less effective in the treatment of serious infections. In the search for novel antibiotics, alternative delivery mechanisms have also been explored. In this study, we report on the encapsulation of vancomycin in PLGA [poly(DL-lactide-co-glycolide)] nanoparticles by electrospraying. The nanoparticles were on average 247 nm in size with small bead formations on the surface. Clusters of various sizes were visible under the SEM (scanning electron microscope). Vancomycin encapsulated in PLGA (VNP) was more effective in inhibiting the growth of S. aureus Xen 31 (MRSA) and S. aureus Xen 36 than un-encapsulated vancomycin. Encapsulated vancomycin had a minimum inhibitory concentration (MIC) of 1 μg/mL against MRSA compared to 5 μg/mL of free vancomycin. At least 70% (w/w) of the vancomycin was encapsulated. Thirty percent of the vancomycin was released within the first 144 h, followed by slow release over 10 days. Vancomycin encapsulated in PLGA nanoparticles may be used to treat serious infections.
Collapse
Affiliation(s)
- Elzaan Booysen
- Department of Microbiology, Faculty of Natural Sciences, Stellenbosch University, Stellenbosch, South Africa
| | - Martin Bezuidenhout
- Department of Industrial Engineering, Faculty of Engineering, Stellenbosch University, Stellenbosch, South Africa
| | - Anton Du Preez van Staden
- Department of Physiological Science, Faculty of Natural Sciences, Stellenbosch University, Stellenbosch, South Africa
| | - Dimiter Dimitrov
- Department of Industrial Engineering, Faculty of Engineering, Stellenbosch University, Stellenbosch, South Africa
| | - Shelly M Deane
- Department of Microbiology, Faculty of Natural Sciences, Stellenbosch University, Stellenbosch, South Africa
| | - Leon M T Dicks
- Department of Microbiology, Faculty of Natural Sciences, Stellenbosch University, Stellenbosch, South Africa.
| |
Collapse
|
8
|
Shabani R, Ashjari M, Ashtari K, Izadyar F, Behnam B, Khoei S, Asghari-Jafarabadi M, Koruji M. Elimination of mouse tumor cells from neonate spermatogonial cells utilizing cisplatin-entrapped folic acid-conjugated poly(lactic-co-glycolic acid) nanoparticles in vitro. Int J Nanomedicine 2018; 13:2943-2954. [PMID: 29849458 PMCID: PMC5965374 DOI: 10.2147/ijn.s155052] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Background Some male survivors of childhood cancer are suffering from azoospermia. In addition, spermatogonial stem cells (SSCs) are necessary for the improvement of spermatogenesis subsequent to exposure to cytotoxic agents such as cisplatin. Objective The aim of this study was to evaluate the anticancer activity of cisplatin-loaded folic acid-conjugated poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) on mouse malignant cell line (EL4) and SSCs in vitro. Methods SSCs were co-cultured with mouse malignant cell line (EL4) cells and divided into four culture groups: 1) control (cells were co-cultured in the culture medium), 2) co-cultured cells were treated with cisplatin (10 μg/mL), 3) co-cultured cells were treated with cisplatin-loaded folic acid-conjugated PLGA NPs, and 4) co-cultures were treated with folic acid-conjugated PLGA for 48 hours. The NPs were prepared, characterized, and targeted with folate. In vitro release characteristics, loading efficiency, and scanning electron microscopy and transmission electron microscopy images were studied. Cancer cells were assayed after treatment using flow cytometry and TUNEL assay. The co-cultures of SSCs and EL4 cells were injected into seminiferous tubules of the testes after treating with cis-diaminedichloroplatinum/PLGA NPs. Results The mean diameter of PLGA NPs ranged between 150 and 250 nm. The number of TUNEL-positive cells increased, and the expression of Bax and caspase-3 were upregulated in EL4 cells in Group 4 compared with Group 2. There was no pathological tumor in testes after transplantation with treated co-cultured cells. Conclusion The PLGA NPs appeared to act as a promising carrier for cisplatin administration, which was consistent with a higher activation of apoptosis than free drug.
Collapse
Affiliation(s)
- Ronak Shabani
- Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.,Department of Anatomical Sciences, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Mohsen Ashjari
- Department of Chemical Engineering, Faculty of Engineering, University of Kashan, Kashan, Iran
| | - Khadijeh Ashtari
- Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.,Department of Medical Nanotechnology and Faculty of Advanced Technology in Medicine, Iran University of Medical Sciences, Tehran, Iran
| | | | - Babak Behnam
- Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.,Department of Medical Genetics and Molecular Biology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.,NIH Undiagnosed Diseases Program, Common Fund, NHGRI, National Institutes of Health, Bethesda, MD, USA
| | - Samideh Khoei
- Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | | | - Morteza Koruji
- Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.,Department of Anatomical Sciences, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| |
Collapse
|